Last updated on December 2018

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #1)


Brief description of study

This Phase III, double blind, placebo and active comparator controlled, multicenter study will investigate the efficacy and safety of etrolizumab in induction of remission in participants with moderately to severely active UC who are naIve to TNF inhibitors and refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment.

Clinical Study Identifier: NCT02163759

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: GA28948 ...

Launceston General Hospital; Gastroenterology Research
Launceston, Australia
  Connect »